Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lymphoma, Large B-Cell, Diffuse | 13 | 2024 | 1433 | 2.420 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 15 | 2024 | 1642 | 1.550 |
Why?
|
Lymphoma, Follicular | 3 | 2022 | 460 | 1.020 |
Why?
|
Immunotherapy, Adoptive | 12 | 2024 | 1502 | 0.820 |
Why?
|
Antibodies, Bispecific | 2 | 2022 | 204 | 0.820 |
Why?
|
Antigens, CD19 | 7 | 2023 | 443 | 0.730 |
Why?
|
Antineoplastic Agents | 10 | 2023 | 13650 | 0.610 |
Why?
|
Mucin-1 | 6 | 2017 | 536 | 0.560 |
Why?
|
Receptors, Antigen, T-Cell | 3 | 2023 | 2568 | 0.560 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2015 | 696 | 0.480 |
Why?
|
Yttrium Radioisotopes | 1 | 2015 | 116 | 0.440 |
Why?
|
Vidarabine | 4 | 2024 | 337 | 0.430 |
Why?
|
Purines | 4 | 2021 | 614 | 0.410 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 13 | 2024 | 11872 | 0.400 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 3 | 2020 | 272 | 0.360 |
Why?
|
Immunoglobulin A | 2 | 2012 | 992 | 0.360 |
Why?
|
Neutropenia | 3 | 2024 | 892 | 0.340 |
Why?
|
Antibodies, Neoplasm | 1 | 2011 | 282 | 0.330 |
Why?
|
Hematopoietic Stem Cell Transplantation | 7 | 2024 | 5716 | 0.320 |
Why?
|
Lymphoma, Mantle-Cell | 2 | 2023 | 238 | 0.310 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 2 | 2012 | 245 | 0.310 |
Why?
|
B-Lymphocytes | 2 | 2022 | 4787 | 0.300 |
Why?
|
Dendritic Cells | 3 | 2017 | 2745 | 0.300 |
Why?
|
Graft vs Host Disease | 4 | 2024 | 3049 | 0.280 |
Why?
|
Immunoglobulin M | 1 | 2012 | 1527 | 0.280 |
Why?
|
T-Lymphocytes | 9 | 2023 | 10254 | 0.270 |
Why?
|
Quinazolinones | 2 | 2019 | 219 | 0.260 |
Why?
|
Thrombocytopenia | 4 | 2022 | 1172 | 0.250 |
Why?
|
Adenine | 5 | 2024 | 995 | 0.250 |
Why?
|
Cyclophosphamide | 5 | 2024 | 2227 | 0.240 |
Why?
|
Lymphoma, B-Cell | 2 | 2022 | 945 | 0.240 |
Why?
|
Vaccination | 2 | 2016 | 3434 | 0.230 |
Why?
|
Remission Induction | 4 | 2021 | 2408 | 0.230 |
Why?
|
Multiple Myeloma | 4 | 2017 | 5186 | 0.230 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 2 | 2017 | 210 | 0.220 |
Why?
|
Chromosomes, Human, Pair 17 | 2 | 2018 | 418 | 0.220 |
Why?
|
Antigens, CD34 | 2 | 2024 | 655 | 0.220 |
Why?
|
Molecular Targeted Therapy | 1 | 2015 | 2824 | 0.210 |
Why?
|
Isoquinolines | 2 | 2021 | 349 | 0.210 |
Why?
|
Piperidines | 5 | 2024 | 1667 | 0.210 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2022 | 1372 | 0.200 |
Why?
|
Pyrazoles | 5 | 2020 | 2028 | 0.200 |
Why?
|
Leukemia, Myeloid, Acute | 4 | 2023 | 3626 | 0.200 |
Why?
|
Antibodies, Monoclonal | 4 | 2016 | 9245 | 0.190 |
Why?
|
Hepatic Veno-Occlusive Disease | 1 | 2023 | 220 | 0.190 |
Why?
|
Cryptosporidiosis | 1 | 2021 | 52 | 0.180 |
Why?
|
Chromosome Deletion | 2 | 2018 | 1384 | 0.170 |
Why?
|
Pyrimidines | 4 | 2020 | 3044 | 0.170 |
Why?
|
Sulfonamides | 2 | 2021 | 1982 | 0.170 |
Why?
|
Leukemia, Prolymphocytic, B-Cell | 1 | 2019 | 1 | 0.170 |
Why?
|
Antigens, Neoplasm | 3 | 2017 | 1997 | 0.160 |
Why?
|
Cancer Vaccines | 3 | 2017 | 1041 | 0.160 |
Why?
|
Vinblastine | 1 | 2019 | 482 | 0.150 |
Why?
|
Humans | 55 | 2024 | 767040 | 0.150 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2019 | 147 | 0.140 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2024 | 9410 | 0.140 |
Why?
|
Transplantation, Homologous | 5 | 2024 | 4838 | 0.140 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2017 | 5332 | 0.140 |
Why?
|
Doxorubicin | 2 | 2024 | 2229 | 0.140 |
Why?
|
Dacarbazine | 1 | 2019 | 552 | 0.130 |
Why?
|
Quinoxalines | 1 | 2018 | 297 | 0.130 |
Why?
|
Signal Transduction | 3 | 2017 | 23621 | 0.130 |
Why?
|
Benzamides | 1 | 2021 | 1376 | 0.130 |
Why?
|
Azacitidine | 1 | 2017 | 336 | 0.130 |
Why?
|
Pyrazines | 1 | 2021 | 1204 | 0.130 |
Why?
|
Radioimmunotherapy | 1 | 2015 | 93 | 0.120 |
Why?
|
Receptors, Antigen, B-Cell | 1 | 2017 | 546 | 0.110 |
Why?
|
Sequence Deletion | 1 | 2018 | 1494 | 0.110 |
Why?
|
Aged | 19 | 2024 | 171319 | 0.110 |
Why?
|
Protein Kinase Inhibitors | 3 | 2019 | 5693 | 0.110 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2017 | 658 | 0.110 |
Why?
|
Autoimmunity | 1 | 2021 | 1361 | 0.110 |
Why?
|
Transplantation, Autologous | 3 | 2023 | 2118 | 0.110 |
Why?
|
Cell Proliferation | 4 | 2017 | 10455 | 0.100 |
Why?
|
Cell Communication | 2 | 2017 | 1660 | 0.100 |
Why?
|
Apoptosis | 4 | 2017 | 9513 | 0.100 |
Why?
|
Peptides | 2 | 2015 | 4348 | 0.100 |
Why?
|
Treatment Failure | 2 | 2024 | 2658 | 0.100 |
Why?
|
Aged, 80 and over | 11 | 2024 | 59548 | 0.100 |
Why?
|
Hematologic Neoplasms | 1 | 2024 | 1907 | 0.100 |
Why?
|
Hodgkin Disease | 1 | 2019 | 1383 | 0.090 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2019 | 2952 | 0.090 |
Why?
|
Stromal Cells | 1 | 2017 | 1335 | 0.090 |
Why?
|
Bone Marrow | 2 | 2020 | 2926 | 0.090 |
Why?
|
Middle Aged | 19 | 2024 | 223233 | 0.090 |
Why?
|
Clinical Trials as Topic | 3 | 2017 | 8048 | 0.080 |
Why?
|
Hemorrhage | 2 | 2020 | 3464 | 0.080 |
Why?
|
Platelet Count | 1 | 2012 | 784 | 0.080 |
Why?
|
Coculture Techniques | 3 | 2017 | 1337 | 0.080 |
Why?
|
Receptors, Interleukin-6 | 1 | 2010 | 224 | 0.080 |
Why?
|
Oxidative Stress | 2 | 2017 | 3139 | 0.080 |
Why?
|
Adult | 15 | 2024 | 223317 | 0.080 |
Why?
|
Recurrence | 3 | 2022 | 8504 | 0.080 |
Why?
|
Anemia, Aplastic | 1 | 2010 | 231 | 0.080 |
Why?
|
Salvage Therapy | 1 | 2015 | 1271 | 0.070 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2017 | 2428 | 0.070 |
Why?
|
Standard of Care | 2 | 2022 | 569 | 0.070 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2020 | 4648 | 0.070 |
Why?
|
Treatment Outcome | 11 | 2024 | 65295 | 0.070 |
Why?
|
Up-Regulation | 2 | 2017 | 4143 | 0.070 |
Why?
|
Antigen Presentation | 1 | 2012 | 1250 | 0.070 |
Why?
|
Thrombopoiesis | 1 | 2008 | 160 | 0.070 |
Why?
|
Immunoglobulin Isotypes | 1 | 1987 | 158 | 0.070 |
Why?
|
Thalidomide | 1 | 2012 | 886 | 0.070 |
Why?
|
Rheumatoid Factor | 1 | 1987 | 185 | 0.070 |
Why?
|
Immunity, Cellular | 1 | 2012 | 1560 | 0.070 |
Why?
|
Lymphocyte Activation | 4 | 2021 | 5499 | 0.060 |
Why?
|
Female | 22 | 2024 | 396660 | 0.060 |
Why?
|
Survival Analysis | 4 | 2020 | 10092 | 0.060 |
Why?
|
Mice, SCID | 3 | 2016 | 2626 | 0.060 |
Why?
|
Neoplastic Stem Cells | 1 | 2013 | 1349 | 0.060 |
Why?
|
Male | 21 | 2024 | 364203 | 0.060 |
Why?
|
Immunoglobulin Heavy Chains | 2 | 2019 | 647 | 0.060 |
Why?
|
Immunosuppressive Agents | 1 | 2018 | 4210 | 0.060 |
Why?
|
Follow-Up Studies | 4 | 2024 | 39317 | 0.060 |
Why?
|
Europe | 1 | 2021 | 3432 | 0.060 |
Why?
|
Neoplasm Staging | 2 | 2020 | 11217 | 0.060 |
Why?
|
Disease-Free Survival | 1 | 2015 | 6844 | 0.060 |
Why?
|
MicroRNAs | 2 | 2017 | 3792 | 0.060 |
Why?
|
Anticoagulants | 1 | 2020 | 4854 | 0.060 |
Why?
|
Neoplasm, Residual | 2 | 2021 | 1012 | 0.060 |
Why?
|
Animals | 10 | 2020 | 168965 | 0.060 |
Why?
|
Medicare | 1 | 2022 | 6813 | 0.050 |
Why?
|
Cell Line, Tumor | 5 | 2017 | 17097 | 0.050 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2017 | 3608 | 0.050 |
Why?
|
Young Adult | 7 | 2024 | 59980 | 0.050 |
Why?
|
Bone Resorption | 1 | 1987 | 726 | 0.050 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 2016 | 3114 | 0.050 |
Why?
|
Polydeoxyribonucleotides | 1 | 2023 | 136 | 0.050 |
Why?
|
Drug Administration Schedule | 2 | 2021 | 4855 | 0.050 |
Why?
|
Prognosis | 4 | 2020 | 29963 | 0.050 |
Why?
|
United States | 3 | 2023 | 72971 | 0.050 |
Why?
|
Stem Cell Transplantation | 1 | 2010 | 1596 | 0.050 |
Why?
|
Vincristine | 1 | 2024 | 1040 | 0.050 |
Why?
|
Intestines | 1 | 2010 | 1905 | 0.050 |
Why?
|
Antigens, CD20 | 1 | 2022 | 199 | 0.050 |
Why?
|
Immunoenzyme Techniques | 2 | 2015 | 1697 | 0.050 |
Why?
|
Immunologic Factors | 1 | 2010 | 1592 | 0.050 |
Why?
|
Mutation | 3 | 2020 | 30211 | 0.050 |
Why?
|
Survival Rate | 1 | 2015 | 12823 | 0.040 |
Why?
|
Leukapheresis | 1 | 2020 | 150 | 0.040 |
Why?
|
Clone Cells | 1 | 2023 | 1669 | 0.040 |
Why?
|
Mice, Inbred NOD | 2 | 2015 | 1837 | 0.040 |
Why?
|
Toll-Like Receptor 9 | 1 | 2020 | 197 | 0.040 |
Why?
|
Mice | 8 | 2020 | 81912 | 0.040 |
Why?
|
Safety-Based Drug Withdrawals | 1 | 2019 | 36 | 0.040 |
Why?
|
Chronic Disease | 3 | 2023 | 9362 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2015 | 6550 | 0.040 |
Why?
|
Dioxygenases | 1 | 2020 | 353 | 0.040 |
Why?
|
Reactive Oxygen Species | 2 | 2017 | 2144 | 0.040 |
Why?
|
Steroids | 1 | 2023 | 937 | 0.040 |
Why?
|
Adolescent | 5 | 2024 | 89046 | 0.040 |
Why?
|
Mice, Mutant Strains | 1 | 2020 | 1751 | 0.040 |
Why?
|
Cross-Priming | 1 | 2017 | 75 | 0.040 |
Why?
|
Perforin | 1 | 2017 | 167 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 4572 | 0.030 |
Why?
|
Methylprednisolone | 1 | 2018 | 386 | 0.030 |
Why?
|
Blotting, Western | 2 | 2015 | 5022 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-jun | 1 | 2017 | 287 | 0.030 |
Why?
|
Cisplatin | 1 | 2022 | 1656 | 0.030 |
Why?
|
Germ Cells | 1 | 2020 | 644 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2021 | 862 | 0.030 |
Why?
|
Safety | 1 | 2020 | 1157 | 0.030 |
Why?
|
Skin Neoplasms | 1 | 2015 | 5859 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2020 | 2227 | 0.030 |
Why?
|
Receptors, Antigen | 1 | 2015 | 51 | 0.030 |
Why?
|
Ribonuclease III | 1 | 2017 | 271 | 0.030 |
Why?
|
Hematologic Diseases | 1 | 2019 | 498 | 0.030 |
Why?
|
Isoantigens | 1 | 2017 | 562 | 0.030 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2016 | 306 | 0.030 |
Why?
|
Dexamethasone | 1 | 2022 | 1963 | 0.030 |
Why?
|
Diarrhea | 1 | 2021 | 1319 | 0.030 |
Why?
|
Cytokines | 2 | 2021 | 7446 | 0.030 |
Why?
|
Fatal Outcome | 1 | 2019 | 1836 | 0.030 |
Why?
|
NADP | 1 | 2015 | 229 | 0.030 |
Why?
|
Severity of Illness Index | 1 | 2012 | 15925 | 0.030 |
Why?
|
Hepatitis, Autoimmune | 1 | 2016 | 173 | 0.030 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2017 | 1352 | 0.030 |
Why?
|
Flow Cytometry | 2 | 2015 | 5891 | 0.030 |
Why?
|
Age of Onset | 1 | 2020 | 3344 | 0.030 |
Why?
|
Janus Kinase 2 | 1 | 2017 | 561 | 0.030 |
Why?
|
Immunomodulation | 1 | 2017 | 548 | 0.030 |
Why?
|
Prednisone | 1 | 2018 | 1566 | 0.030 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2015 | 414 | 0.030 |
Why?
|
Incidence | 1 | 2021 | 21526 | 0.030 |
Why?
|
Glutathione | 1 | 2015 | 589 | 0.030 |
Why?
|
STAT3 Transcription Factor | 1 | 2017 | 872 | 0.030 |
Why?
|
Drug Synergism | 1 | 2016 | 1759 | 0.020 |
Why?
|
Age Factors | 2 | 2020 | 18401 | 0.020 |
Why?
|
Arthritis, Rheumatoid | 1 | 1987 | 3778 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2015 | 20741 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2017 | 998 | 0.020 |
Why?
|
Immune System | 1 | 2016 | 799 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2017 | 2221 | 0.020 |
Why?
|
Administration, Oral | 1 | 2019 | 4026 | 0.020 |
Why?
|
Transcriptional Activation | 1 | 2017 | 1751 | 0.020 |
Why?
|
Biological Products | 1 | 2020 | 948 | 0.020 |
Why?
|
Necrosis | 1 | 2015 | 1614 | 0.020 |
Why?
|
Anemia | 1 | 2020 | 1514 | 0.020 |
Why?
|
Cross-Sectional Studies | 1 | 2012 | 26325 | 0.020 |
Why?
|
Gene Silencing | 1 | 2017 | 1505 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2017 | 1854 | 0.020 |
Why?
|
Nervous System Diseases | 1 | 2020 | 1660 | 0.020 |
Why?
|
Infant | 1 | 2012 | 36485 | 0.020 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2015 | 1150 | 0.020 |
Why?
|
Neoplasms | 2 | 2015 | 22350 | 0.020 |
Why?
|
RNA, Messenger | 2 | 2015 | 12793 | 0.020 |
Why?
|
Interferon-gamma | 1 | 2017 | 3154 | 0.020 |
Why?
|
Child, Preschool | 1 | 2012 | 42606 | 0.020 |
Why?
|
Immunoblotting | 1 | 2012 | 1647 | 0.020 |
Why?
|
Boston | 1 | 2021 | 9360 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2013 | 1864 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2018 | 2163 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2020 | 4522 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2023 | 12536 | 0.020 |
Why?
|
Cell Differentiation | 2 | 2017 | 11657 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2020 | 4405 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2015 | 6106 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2013 | 2509 | 0.020 |
Why?
|
Benzoates | 1 | 2008 | 213 | 0.020 |
Why?
|
Hydrazines | 1 | 2008 | 223 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2018 | 8535 | 0.020 |
Why?
|
Thrombopoietin | 1 | 2008 | 225 | 0.020 |
Why?
|
Arthrography | 1 | 1987 | 149 | 0.020 |
Why?
|
Cohort Studies | 2 | 2018 | 41718 | 0.020 |
Why?
|
Receptors, Fc | 1 | 2008 | 537 | 0.020 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2015 | 2887 | 0.010 |
Why?
|
Tumor Microenvironment | 1 | 2017 | 3944 | 0.010 |
Why?
|
T-Lymphocyte Subsets | 1 | 2012 | 1814 | 0.010 |
Why?
|
Retrospective Studies | 3 | 2024 | 81659 | 0.010 |
Why?
|
Gene Expression | 1 | 2017 | 7587 | 0.010 |
Why?
|
Child | 1 | 2012 | 80771 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2020 | 9612 | 0.010 |
Why?
|
Autoimmune Diseases | 1 | 2015 | 2255 | 0.010 |
Why?
|
Inflammation | 1 | 2021 | 10869 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2017 | 8628 | 0.010 |
Why?
|
Quality of Life | 1 | 2022 | 13485 | 0.010 |
Why?
|
Liver | 1 | 2016 | 7578 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2008 | 3738 | 0.010 |
Why?
|
Time Factors | 1 | 2021 | 40154 | 0.010 |
Why?
|
Biopsy | 1 | 2010 | 6777 | 0.010 |
Why?
|
Hepatitis C | 1 | 2008 | 1594 | 0.010 |
Why?
|
Blood Platelets | 1 | 2008 | 2464 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2015 | 22254 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2015 | 11923 | 0.010 |
Why?
|
Carrier Proteins | 1 | 2008 | 4925 | 0.010 |
Why?
|